The effect of mebeverine on the quality of life of patients with irritable bowel syndrome in the Tuzla Canton
DOI:
https://doi.org/10.5457/ams.v51i1-2.622Keywords:
the most commonly used medicines, patients with irritable bowel syndrome, mebeverineAbstract
By definition, irritable bowel syndrome (IBS) is a chronic disorder of the gastrointestinal tract, characterised by abdominal pain and changes in the bowel movement, without any detectable organic disease (no histological, morphological, biochemical, or microbiological abnormality). The study included 200 patients with irritable bowel syndrome who had a colonoscopy performed and were diagnosed with irritable bowel syndrome using the Rome IV criteria. From January to April of 2018, the study was conducted as a prospective cohort study at the University Clinical Center Tuzla (UCC). The participants were surveyed during the initial exam and on week four and eight after the administered therapeutic protocol. The aim of the study was to determine the most commonly used medicine for treatment of symptoms of irritable bowel syndrome in the Tuzla Canton. Results: The most commonly prescribed medicine after the diagnosis of irritable bowel syndrome was mebeverine as monotherapy or mebeverine in combination with an antidepressant. Discussion: Even though there are more than 50 registered medicines for the treatment of irritable bowel syndrome in the Tuzla Canton, probably due to its availability most often mebeverine was the medicine of choice. Conclusion: After the colonoscopy and the diagnosis of irritable bowel syndrome, regardless of the age, sex, or the subtype of irritable bowel syndrome, mebeverine was the first choice of medicine.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
